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Abstract: Magnesium (Mg) deficiency might be a catalyst in the process of endothelial dysfunction,
an early event in the pathogenesis of atherosclerosis. The aim of this study was to determine the
acute effect of an oral Mg supplement as compared to control on endothelial function assessed by
flow-mediated dilatation (FMD). Nineteen participants (39 years, body mass index (BMI) 22.9 kg/m2 )
completed this randomized cross-over study. Blood pressure (BP) and FMD were measured and
blood samples were taken before participants drank 200 mL water, with or without an over the
counter Mg supplement (450 mg and 300 mg for men and women). Measurements were repeated
at 60 and 120 min. There was a statistically significant two-way interaction between treatment and
time on serum Mg (p = 0.037). A difference of −0.085 mm in FMD was observed 60-min post drink in
the control group, as compared to baseline FMD, and no difference was observed in the supplement
group as compared to baseline. Despite the non-significant interaction between treatment and time
on FMD, once adjusted for baseline, the difference seen in the control group and the lack of change
in the supplement group at 60 min post-drink suggests that Mg might attenuate the reduction in
FMD post-prandially.
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Cardiovascular disease (CVD) is the leading cause of death worldwide with 31% of
all global deaths attributed to CVD [1]. Magnesium (Mg) is emerging as a nutrient of
importance in cardiovascular health [2–6]. Low serum Mg is associated with increased
coronary artery disease (CAD) risk [6]. In a large study of 14,446 participants over 27 years,
during which 2131 cases of CAD cases were seen, it was observed that low serum Mg
was associated with higher CAD [6]. Dietary magnesium might reduce all-cause mortality
as seen in a recent meta-analysis with each additional intake of 100 mg/d of dietary
magnesium being associated with a 6% risk of all-cause mortality. [7]. It is unclear what the
potential mechanism for this effect might be, but there is evidence that fruit and vegetable
intake is inversely associated with CVD risk [8]. Several minerals might contribute to this
beneficial effect including reducing sodium [9–12] and increasing potassium intakes [13–15],
and increased Mg intake [3].
The main underlying cause of CVD is atherosclerosis with endothelial dysfunction as
an early event in its pathogenesis [16,17]. Flow-mediated dilatation (FMD), an ultrasound
measurement of the brachial artery, is a non-invasive technique for measurement of endothelial function and is a useful surrogate measure of the endothelial function in coronary
arteries [18,19]. Higher dietary Mg intake and serum Mg concentrations are inversely
associated with endothelial dysfunction and markers of inflammation [20–22]. A recent
meta-analysis suggests that chronic Mg supplementation over 6 months might improve
FMD in overweight or older individuals [23,24]. However, this was not confirmed in
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a randomized placebo-controlled 24-week study with 350 mg of Mg in 52 overweight and
obese subjects. FMD was measured in the fasting state and whether there was any effect on
post-prandial FMD, remains unknown. Therefore the aim of this study was to investigate
the acute effect of Mg supplementation on post-prandial FMD to determine its effect on
endothelial function in the post-prandial state.
2. Materials and Methods
2.1. Volunteers
Participants aged 18–75 years, BMI 18–35 kg/m2 and SBP < 140 mm, DBP < 90 mm,
were recruited via public advertisement, using flyers and social media posts. They were
screened for eligibility prior to attending their first visit. Participants were weight stable
in the preceding 6 months, and were not currently taking cholesterol or antihypertensive
medication, non-steroidal anti-inflammatory medications, drugs affecting endothelial
function, or folate supplementation.
2.2. Trial Protocol
At a screening visit in which participants eligibility for the trial was confirmed, body
height and weight and blood pressure (BP) was measured, and instructions on how to
complete a 3-day food diary and 24-h urine collection were given. In two subsequent
visits, measurements of BP and flow-mediated dilatation (FMD) were taken, and a blood
sample was collected at time-point 0 before consuming a 200-mL drink, with or without
an Mg supplement in a randomized manner. These measurements were collected again at
60- and 120-min after drink consumption. Supplementation was over-the-counter Mg citrate supplements ([25] Wellness, Australia) either 3 × 150 mg for men or 2 × 150 mg
for women. The dose was equivalent to 300 mg/day for women and 450 mg/day
for men, with the aim of meeting the Australian recommended daily intake (RDI) of
400–420 mg/day and 310–320 mg/day for men and women, respectively [26]. Given that
the RDI might be too low, given the rising body weights, we calculated an Mg supplement
dose /kg variable and used this as a covariate in the analysis [27]. This trial was approved
by the University of South Australia’s Human Research Ethics Committee (approval number: 0000035834) and is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR; number 12617000160336). All participants gave written informed consent.
An honorarium of $150 was offered to participants once they had completed all
study visits.
An online generated random number allocation sequence was used to randomize the
order of the visits (www.randomization.com; accessed on 30 January 2017). Randomization
was performed by a research team member that did not complete the FMD measurements
and the code was stored on a password-protected computer.
At the screening visit, participants’ body height was measured to the nearest
0.01 cm (SECA, Hamburg, Germany), whilst barefoot. Body weight was also measured
via electronic scales to the nearest 0.05 kg (SECA Hamburg, Germany) at each study visit.
Participants wore light clothing and wore no footwear.
Participants were asked to complete a 3-day weighed food diary (one weekend day
and two weekdays) prior to their first visit, to determine their habitual dietary intakes of
Mg. Analysis of the food diaries was conducted via the Foodworks Profession Edition
2007 (version 5; Foodworks Professional Edition; Xyris Software, Highgate Hill, Australia). They also collected a 24-h urine sample, prior to their first visit. A total weight
of the 24-h urine sample was recorded, with a 20–30 mL aliquot sent to an accredited
laboratory (SA Pathology, Adelaide, South Australia) for analysis of urinary Mg and
creatinine concentration.
Blood pressure was measured using an automated sphygmomanometer (SureSigns V3;
Philips, North Ryde, Australia) with participants seated. A series of 4 consistent measures
were obtained, within range of 10 mm, with the first reading discarded. The average of the
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remaining measurements was calculated. Measurements were taken at time point 0, and
then at 60 min and 120 min, following the drink at visit 1 and 2.
2.3. Flow Mediated Dilatation (FMD)
Flow-mediated dilatation (FMD) measurements were performed by a single trained
operator (PMC), in a quiet temperature-controlled room. All participants were fasting.
Endothelium-dependent FMD of the right brachial artery was measured in the longitudinal
plane, above the antecubital fossa, with an 8.8-MHz linear array transducer (GE Logiq
5). The brachial artery diameter was measured before and after forearm ischemia caused
by inflation of a sphygmomanometer cuff applied to the right forearm, 2-cm below the
olecranon process to 200 mmHg, for 5 min. The operator was blinded to participant
condition and the measures were recorded at time-point 0, as well as 60- and 120-min
post drink ± supplementation consumption. All recorded images were stored offline for
analysis at a later point, and encoded to ensure blind analysis.
Ultrasound images were recorded at a rate of 30 frames per second, with screen capture
software (Debut Video Capture Software Professional V1.82; NCH Software, Canberra,
Australia), and were analyzed with edge-detection software (Brachial Analyser for Research
V6.1.3; Medical Imaging application LLC, Coralville, Iowa, USA), to determine artery
diameter (mm) values for both baseline and deflation. Baseline was defined as the average
15-s pre inflation, and peak diameter was determined as the maximum diameter post-cuff
release. The absolute change in artery diameter (mm) was then calculated as the difference
between the two.
2.4. Serum Magnesium
Blood samples were collected via cannular insertion into the left brachial vein at each
study visit. Samples were collected at baseline, and then 60 and 120 min following the drink
± supplement for analysis of Mg. Two × 8 mL serum separator clot activator tubes were
collected and left to clot for 30 min at room temperature. One tube was then centrifuged
at 4000 RPM for 10 min (Universal 32R; Hettich Zentrifugen, Tuttlingen, Germany) and
aliquots of the serum were stored at −80 degrees Celsius, with the other delivered to SA
Pathology, Adelaide, South Australia for analysis.
Based on a previous studies 32–35 subjects would be required to detect a mean
difference in FMD of 0.04 mm (α = 0.05; 80% power) between treatments. A pilot study
was conducted (4 males, 17 females) to determine the power needed for a larger study and
to explore the protocol to determine its efficacy and if a larger study was needed.
2.5. Statistics
Data were analyzed using the IBM SPSS software (version 21; IBM, Chicago, IL,
USA). Significance was set at p < 0.05. A two-way ANOVA with repeated measures (with
treatment and time as the within-subject factors) was used, with and without covariates
including SBP, DBP, MAP, age, BMI, and serum Mg, Mg dose/body weight in Kg, and
gender as a between-subjects’ factor. Spearman Rho correlation analyses was used to assess
the association between dietary Mg intake and urinary Mg excretion, and the association
between dietary Mg intake and baseline FMD. A backwards linear regression was used to
explore the association between FMD, age, and dietary variables, including saturated fat,
polyunsaturated fat, and dietary Mg intake and supplement dose in mg/kg body weight.
All data are expressed as mean ± SD or median ± inter-quartile (IQR) as appropriate.
3. Results
Twenty-one healthy volunteers were enrolled in the study, and 19 completed it. Baseline characteristics are outlined in Table 1. FMD, SBP, DBP, and MAP were analyzed for all
completers, however, several serum MG values were missing due to blood samples not
being successfully collected. Weight was not different between visits.
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Table 1. Baseline characteristics (n = 21).

Age (years)
Weight (kg)
Height (cm)
BMI (kg/m2 )
SBP (mmHg)
DBP (mmHg)
MAP (mmHg)
24 h urine Mg excretion (mmol/L)
24 h urine Cr excretion (mmol/L)
Timepoint 0 brachial artery diameter (mm)
Baseline serum mg (mmol)

Range

Mean/Median

SD/IQR

19–75
45.8–100.9
157–180
17.9–31.9
92–134
65–90
75–101.7
2.03–5.23
3.64–20.0
3.01–5.20
0.75–0.94

39
59.2 (median)
166.6
21.1 (median)
113.5
76.2
88.5
3.39
8.82 (median)
3.8
0.85

16
14.2 (IQR)
6.5
5.6 (IQR)
13.8
7.2
8.7
0.86
3.19 (IQR)
0.56
0.047

3.1. Dietary Intake
Table 2 outlines the usual dietary intake levels of Mg, saturated fat, and PUFA, as
recorded by 3-day weighed food records, 53% of participants did not meet the RDI for
Mg for their respective age and gender, and 26% did not meet the estimated average
requirement (EAR) for Mg for their respective age and gender.
Table 2. Usual dietary intake as determined by 3-day weighed food records.
Nutrient

Range

Mean

SD

Mg Intake (n = 19) mg/day
Male Mg Intake (n = 4)
Female Mg Intake (n = 15)
Saturated Fat Intake (n = 19) g/day
Male Saturated Fat Intake (n = 4)
Female Saturated Fat Intake (n = 15)
PUFA Intake (n = 19) g/day
Male PUFA Intake (n = 4)
Female PUFA Intake (n = 15)

138–510
199–429
138–510
6.7–57.9
15.3–57.9
6.7–46.4
1.5–24.9
5.8–17.7
1.5–24.9

339
328
343
27.7
33.5
26.1
12.5
10.1
13.2

106.7
51.0
97.7
13.7
17.8
12.7
6.2
5.2
6.4

SD = standard deviation; Mg = Magnesium; and PUFA = polyunsaturated fat.

3.2. Flow-Mediated Dilatation
There was no interaction between treatment and time (60 and 120 min) for absolute
FMD (F (2, 36) = 1.371, p = 0.27). The main effect of treatment showed a difference
in absolute FMD between treatments (F (2, 18) = 4.948, p = 0.04), which was due to
average time-point 0 (pre-supplement) differences in absolute FMD of 0.076 mm, between
the supplement and the control group (p = 0.02) (Figure 1). Time by treatment for all
3 time-points was not significant when the difference between baseline FMD was added
as a covariate. Similarly, there was no treatment by time effect when examining baseline
and 120 min There was no significant effect of age, gender, BMI, or serum Mg (between
groups or time-points) or Mg dose in relation to body weight, when used as covariates. At
time-point 60, a difference of −0.085 mm was observed in the control group as compared to
time-point 0, with no change observed in the supplement group across the same time-frame.
3.3. Blood Pressure and Mean Arterial Pressure
There was no interaction between treatment and time on SBP or DBP. No changes
were observed between treatments or any time-point for either SBP or DBP. Age, gender,
or differences in serum Mg (between groups or time-points) had no impact on SBP or DBP.
No interaction between treatment and time was observed for MAP, and furthermore there
were no differences in MAP between treatments or time-points F (1, 18) = 0.509, p = 0.49,
F (2, 36) = 0.82, p = 0.45, respectively. Age, gender, or differences in serum Mg (between
groups or time-points) had no effect on MAP.
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Figure 2. Association between Urinary and Dietary Magnesium.
Figure 2. Association between Urinary and Dietary Magnesium.
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patients on haemodialysis [35], participants had baseline serum Mg concentrations within
normal ranges. There is a need for further studies in participants with low serum Mg
concentrations, to assess the effects on endothelial function, as measured by FMD.
4.3. Strengths and Limitations
The strengths of this study include that the same operator undertook all FMD measurements for the study, who was blinded to the treatments at the time of measurement.
Limitations of the study incude the small sample size and the lack of a placebo. As these
were healthy volunteers with a normal FMD, we can only conclude that magnesium had
no acute effect in this group and it might have a beneficial effect in people with CV disease
or risk factors and a low FMD. This is the first study we are aware of that examined the
effect of magnesium acutely. We previously showed that both sodium and potassium can
have acute effects, so it was possible that magnesium might also have an acute as well
as a chronic effect. Although we did not find an effect, we believe the area should be
investigated further and that magnesium might be a useful supplement for people with
impaired FMD.
5. Conclusions
The difference in FMD in the control group and the lack of change in the supplement group at 60-min post-drink suggests that Mg attenuates the reduction in FMD
post-prandially. Further research is warranted to investigate the potential beneficial effect
of MG supplementation on post-prandial endothelial function.
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